Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes 56:e4 2007
DOI: 10.2337/db07-0216
© 2007 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boden, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Boden, G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Letter to the Editor

Response to Comment on: Boden et al. (2007) Combined Use of Rosiglitazone and Fenofibrate in Patients with Type 2 Diabetes: Prevention of Fluid Retention: Diabetes 56:248–255

Guenther Boden

From the Temple University Hospital, Philadelphia, Pennsylvania

Address correspondence to Guenther Boden, Temple University Health Science Center, General Clinical Research Center, 3401 North Broad St., 4W, Philadelphia, PA 19140-6148. E-mail: bodengh{at}tuhs.temple.edu

We agree with Drs. Karalliedde and Viberti (1) that our findings (2) are preliminary. First, we studied only a small number of patients. Moreover, our finding that therapy with rosiglitazone plus fenofibrate prevented the expected rosiglitazone-induced water retention was completely unanticipated and rather surprising. Clearly, therefore, this intriguing observation needs to be confirmed with a much larger number of patients and in much greater detail.

Received for publication February 15, 2007 and accepted in revised form February 17, 2007

REFERENCES

  1. Karalliedde J, Viberti GC: Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248–255. Diabetes 56:e3, 2007. DOI: 10.2337/db07-0146[Free Full Text]
  2. Boden G, Homko C, Mozzoli M, Zhang M, Kresge K, Cheung P: Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention. Diabetes 56:248–255, 2007[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Boden, G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Boden, G.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum